TEMENOS
2.3.2021 08:32:08 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Croí Laighean Credit Union has selected Temenos front-to-back Software-as-a-Service (SaaS) to transform its digital banking. This strategic move from a legacy, on premise system to a community banking solution powered by Temenos SaaS will ensure that Croí Laighean has the technology it needs now and into the future to compete on a level playing field with the big banks and fintech challengers. For Croí Laighean, a strong community presence and the best in digital banking is a winning combination that will help the credit union to differentiate with a service that appeals to members and supports growth.
Paul Kennedy, CEO, Croí Laighean, commented: “We are delighted to partner with Temenos to transform our digital banking capability. The Temenos platform puts us on a par technologically with the world’s biggest banks. The move from on premise software to Temenos SaaS was a strategic decision that will set us up for success long into the future. We are already well on the way to transitioning to the new system and look forward to launching new products and experiences for the benefit of our members this year.”
David Macdonald, President of Europe, Temenos, said: “We are proud to welcome Croí Laighean to the growing community of credit unions choosing Temenos SaaS to accelerate their digital ambitions and attract a new generation of members. The flexible deployment capabilities of our community banking solution is ideal for the credit unions in Ireland, delivering the opportunity for a fully managed service that is secure, resilient and future-proof. This is a big step forward for Croí Laighean and the start of an exciting journey for its members.”
Hosted on Microsoft Azure in Microsoft’s Dublin data center, the service is already in use by a number of other credit unions in Ireland, including Capital Credit Union, Credit Union Plus and Tullamore Credit Union.
Temenos’ community banking solution offers pre-packaged, front-to-back credit union products, processes and channels, all built on modern cloud-native and API-first technology. It gives Croí Laighean the capability to offer outstanding digital member experiences, bring new products to market faster and achieve efficiencies through increased automation and digitization of processes. Delivered as SaaS, Croí Laighean is always up-to-date with the latest in digital banking technology without the cost and risk of maintaining on premises systems.
The Covid-19 pandemic has accelerated the shift towards digital banking and Temenos SaaS will help Croí Laighean to provide more member-friendly services, more efficiently, via mobile app on online. Before the pandemic, 60% of Croí Laighean members’ weekly transactions were in branch compared to 40% via digital channels. By the start of 2021, the proportion of weekly transactions via digital had increased to over 80% and this is trend is only expected to continue.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
About us
Croí Laighean Credit Union now has over 38,000 members in our common bond which stretches from Rhode, Co. Offaly in the West to Leixlip, Co. Kildare in the East. We now have 7 branches: Edenderry, Coill Dubh, Clane, Leixlip, Allenwood, Carbury and Prosperous.
For more information, please visit www.clcu.ie
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005641/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom